$KO

Stocks making the biggest moves premarket: Coca-Cola, Sherwin-Williams, Johnson & Johnson & more

Premarket movers included Coca-Cola, Sherwin-Williams, Hilton, Johnson & Johnson, Corning, Cadence Design Systems, Rambus, Universal Health Services, Welltower, Happen (formerly LendingClub), and Cincinnati Financial. Key catalysts were earnings beats or misses and guidance changes, including J&J’s $5.5 billion talc settlement and Coca-Cola’s raised outlook after EPS and revenue topped estimates.

Original reporting
Published Jul 28, 2026, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stocks making the biggest moves premarket: Coca-Cola, Sherwin-Williams, Johnson & Johnson & more — source image
Decision brief

The 30-second read

$KOBullishMed
01

Why it matters

The actionable signal is the direction and specificity of guidance versus consensus, plus quantified settlement costs for JNJ. The largest premarket moves are driven by either raised full-year outlooks (KO, SHW, WELL, LC) or lowered/missed guidance (HLT, UHS) and a sharp reaction to mixed results (GLW, RMB).

02

Market read

Traders can use the premarket guidance direction versus consensus to position for open volatility and potential estimate revisions.

03

What to watch

For the biggest movers (notably GLW and RMB), the article does not provide the full guidance or magnitude of expectation changes, so traders should verify management commentary and full outlook tables before sizing.

Relevance 7/10Novelty 6/10Timing: premarket, ahead of the open

Background

This is a CNBC pre-bell market wrap highlighting which stocks are moving on earnings results and guidance changes.

Company-level read

Ticker impact

$KOBullishHigh confidence
Context

Coca-Cola shares rose 2% after it topped earnings expectations and hiked its full-year outlook with specific EPS and revenue beats.

Expected impact

Likely continued strength into the open if guidance is viewed as credible versus Street expectations.

Evidence & confidence

The article cites both EPS and revenue beats and a full-year outlook hike, which typically drives estimate revisions and sentiment.

$SHWBullishMedium confidence
Context

Sherwin-Williams gained nearly 6% after second-quarter results beat expectations and it raised its full-year earnings outlook.

Expected impact

Potential follow-through higher, though magnitude may fade if the market already priced the beat.

Evidence & confidence

The text provides beat figures and an outlook hike, but does not quantify how much guidance changed versus prior consensus beyond direction.

$HLTBearishHigh confidence
Context

Hilton Worldwide fell 2.7% after third-quarter guidance missed expectations, despite a Q2 earnings and revenue beat.

Expected impact

Likely pressure at the open until investors re-anchor on the Q2 beat versus the weaker near-term guide.

Evidence & confidence

The article explicitly contrasts a guidance miss (EPS range vs consensus) with a Q2 beat, making the guidance the key driver.

$JNJBullishMedium confidence
Context

Johnson & Johnson rose more than 2% after agreeing to settle thousands of talc lawsuits for a combined $5.5 billion.

Expected impact

Moderately positive reaction with potential volatility as investors assess financial impact and remaining litigation.

Evidence & confidence

A large, quantified settlement is a concrete catalyst, but the article does not provide balance-sheet context or how it compares to expectations.

$GLWBearishMedium confidence
Context

Corning plunged 16% on a mixed quarterly report, with the current-quarter revenue guidance cited as about in line with consensus.

Expected impact

Likely continued weakness at the open given the magnitude of the premarket drop, unless buyers step in on the beat portion.

Evidence & confidence

The article states Q2 beats but highlights current-quarter revenue guidance as about in line, which can still disappoint if investors expected upside.

$CDNSBullishHigh confidence
Context

Cadence Design Systems rose about 3% after posting Q2 adjusted EPS of $2.11, beating LSEG consensus, with revenue in line.

Expected impact

Possible modest follow-through higher, but upside may be capped by the lack of revenue surprise.

Evidence & confidence

The catalyst is specific: adjusted EPS beat versus consensus, while revenue matched expectations.

$UHSBearishHigh confidence
Context

Universal Health Services dropped 3% after lowering full-year guidance, with adjusted EPS range reduced versus prior outlook.

Expected impact

Downward pressure likely persists at the open as investors price in lower full-year earnings.

Evidence & confidence

The article provides the before-and-after full-year EPS ranges, making the guidance reduction the direct driver.

$WELLBullishHigh confidence
Context

Welltower climbed 4.5% after raising full-year guidance for normalized funds from operations to $6.36 to $6.44 per share.

Expected impact

Potential continuation higher at the open, especially if the raised range is seen as durable.

Evidence & confidence

The article includes a specific raised FFO range and states it exceeds FactSet consensus.

Market effects

Guidance beats and cuts across consumer staples, industrials, healthcare, and financials reinforce that investors are trading earnings quality and forward outlook, not just headline EPS.

Primarily US large-cap and mid-cap sentiment into the cash open; limited direct cross-region linkage in the text.

No explicit global macro or international regulatory catalysts mentioned; impacts are company-specific.

Counterpoint

Some names rose on beats but could fade if the market already priced the consensus and focuses on forward margins or guidance details not fully covered here.

Key entities

  • Coca-Cola

    Topped earnings and revenue expectations and raised full-year outlook, lifting shares premarket.

  • Sherwin-Williams

    Beat Q2 results and raised full-year earnings outlook, pushing shares higher premarket.

  • Hilton Worldwide

    Third-quarter guidance missed consensus, weighing on shares despite a Q2 beat.

  • Johnson & Johnson

    Agreed to a $5.5 billion talc lawsuit settlement, supporting the stock premarket.

  • Corning

    Shares fell sharply on a mixed quarter, with current-quarter revenue guidance about in line.

Related articles

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$KOMedAI 8/10

Step Aside, Coca-Cola and Bank of America: There's a New Apple of Berkshire Hathaway's Eye, and It's a Virtual Monopoly

Berkshire Hathaway's new CEO Greg Abel has reshuffled the company's investment portfolio, reducing stakes in Coca-Cola (KO) and Bank of America (BAC) while increasing holdings in Alphabet (GOOGL, GOOG). Alphabet is now Berkshire's third-largest holding, valued at $16 million more than its Coca-Cola stake. Abel has committed $17 billion to Alphabet, including a $10 billion private placement, citing its virtual monopoly in search and AI growth potential.

$JNJMedAI 8/10

J&J’s 64-Year Dividend Streak Reinforces ‘Sleep-Well’ Stock Status

Johnson & Johnson (JNJ) raised its dividend for the 64th consecutive year, increasing the quarterly payout by 3.1% to $1.34 per share. The company reported a 7% sales increase to $25.31 billion in the latest quarter, driven by oncology and immunology drugs. JNJ raised its 2026 revenue guidance to $101.1 billion and plans to introduce 20 new therapies by 2030. The company maintains a AAA credit rating and is resolving talc-related lawsuits.

$JNJMedAI 8/10

Johnson & Johnson (JNJ)’s Imaavy Expands Into Rare Blood Disorder: What Investors Should Know

Johnson & Johnson (JNJ) received FDA approval for Imaavy to treat warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older. This is the first approved treatment for this group. The drug, already approved for generalized myasthenia gravis, showed significant improvement in hemoglobin levels in clinical trials. JNJ expects Imaavy to have over $5 billion in peak sales potential, though the wAIHA market is relatively small.

$JNJHighAI 9/10

Johnson & Johnson Just Got a Big FDA Win

Johnson & Johnson (JNJ) received FDA approval for Imaavy, a drug to treat warm autoimmune hemolytic anemia in patients aged 12 and older. This marks JNJ's second FDA approval in two months, following its dual-energy ablation catheter for atrial fibrillation. The company operates in medical technology and pharmaceuticals after spinning off its consumer business in 2023.

$PEPMedAI 8/10

Pepsi vs. Coke: One Stock Is Starting to Pull Ahead

Coca-Cola (KO) raised full-year guidance, reporting 5% global volume growth and a 34.9% operating margin, while PepsiCo (PEP) reaffirmed guidance with a 14.4% margin. KO shares surged 33% year-to-date, outperforming PEP's 3% gain. Coke's asset-light model and World Cup boost contrast with Pepsi's volume shortfalls and consumer weakness concerns.